Loading...
New oral contraceptive (OC) formulations feature shorter hormone-free intervals or continuous use of hormones (Journal Watch Women’s Health Aug 31 2006). In a manufacturer-sponsored, open-label North American trial, investigators assessed the efficacy and safety of a continuous OC formulation combining 20 μg ethinyl estradiol and 90 μg levonorgestrel (similar to Alesse and Levlite). The study OC was supplied in 28-day packs of identical tablets with no pill-free intervals. Participants completed diaries throughout the year, noting the occurrence of bleeding (which required sanitary protection) and spotting (which did not); amenorrhea was defined as the absence of bleeding and spotting. Pregnancy tests were administered at 28-day intervals.
O…